Search - tctmd.com

Displaying 41 - 60 of 2033

Sort: Relevancy | Date

FDA Expands Evolut Indication to Include Redo TAVI

News Daily News

FDA Expands Evolut Indications to Include Redo TAVI

Yael L. Maxwell

August 29, 2025

News Conference News ESC 2025

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

Michael O'Riordan

August 29, 2025

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

News Daily News

SCAI/HRS Issue First Practice Guideline for LAAO

Yael L. Maxwell

August 06, 2025

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

Podcast TCTMD Talking Points

Echocardiography and Quality Data

August 04, 2025

News Industry News

Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe

August 01, 2025

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

L.A. McKeown

July 24, 2025

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

News Daily News

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

Caitlin E. Cox

July 14, 2025

News Conference News NY Valves 2025

Promising Early Data With Navitor TAVI Valves

Yael L. Maxwell

July 02, 2025

Presentation NY Valves 2025

Outcomes of TEE vs. ICE-guided Left Atrial Appendage Closure Using a Fluoropolymer Coated Device: A Sub-analysis of the HEAL-LAA Post Approval Study

Presenter: Seun Alli

June 26, 2025

Presentation NY Valves 2025

Outcomes in Patients Discharged on OAC vs. DAPT After Left Atrial Appendage Occlusion Using a Fluoropolymer Coated Device: A Sub-analysis of the HEAL-LAA Post Approval Study

Presenter: Seun Alli

June 25, 2025

Presentation NY Valves 2025

Outcomes of Same-day vs. Delayed Discharge After LAAC Using a Fluoropolymer Coated Device: HEAL-LAA Post Approval Study Sub-analysis

Presenter: Jeremiah P. Depta

June 25, 2025

News Daily News

‘Sobering’ Adverse Event Rate With Evoque Seen in Real-world Use

Yael L. Maxwell

June 18, 2025

News Industry News

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

June 12, 2025

News Daily News

FDA Approves Triple Therapy Polypill for High Blood Pressure

Michael O'Riordan

June 10, 2025

News Daily News

Tendyne Approved in US for High-risk Patients With Mitral Valve Disease

Michael O'Riordan

May 28, 2025

News Daily News EuroPCR 2025

Underexpanded Acurate neo2 Valves Tied to Worse Outcomes: ACURATE IDE

Michael O'Riordan

May 28, 2025

News Conference News EuroPCR 2025

IVL Effective in Severely Calcified Lesions, Especially in Women

Yael L. Maxwell

May 22, 2025

Advertisement

FDA Expands Evolut Indications to Include Redo TAVI

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

Evolocumab Gains Expanded Indication for Primary Prevention

SCAI/HRS Issue First Practice Guideline for LAAO

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Echocardiography and Quality Data

Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

Promising Early Data With Navitor TAVI Valves

Outcomes of TEE vs. ICE-guided Left Atrial Appendage Closure Using a Fluoropolymer Coated Device: A Sub-analysis of the HEAL-LAA Post Approval Study

Outcomes in Patients Discharged on OAC vs. DAPT After Left Atrial Appendage Occlusion Using a Fluoropolymer Coated Device: A Sub-analysis of the HEAL-LAA Post Approval Study

Outcomes of Same-day vs. Delayed Discharge After LAAC Using a Fluoropolymer Coated Device: HEAL-LAA Post Approval Study Sub-analysis

‘Sobering’ Adverse Event Rate With Evoque Seen in Real-world Use

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

FDA Approves Triple Therapy Polypill for High Blood Pressure

Tendyne Approved in US for High-risk Patients With Mitral Valve Disease

Underexpanded Acurate neo2 Valves Tied to Worse Outcomes: ACURATE IDE

IVL Effective in Severely Calcified Lesions, Especially in Women

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content